Dose-dependent improvements in learning and memory deficits in APPPS1-21 transgenic mice treated with the orally active Aβ toxicity inhibitor SEN1500

Neuropharmacology

Volumn 75, Issue , 2013, Pages 458-466

  Lo, Adrian C ^a,c   Tesseur, Ina ^a,b,c   Scopes, David I C ^d   Nerou, Edmund ^d   Callaerts Vegh, Zsuzsanna ^a,c   Vermaercke, Ben ^a,c   Treherne, J Mark ^d   De Strooper, Bart ^a,b,c   D'Hooge, Rudi ^a,c  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^c Leuven Research Institute for Neuroscience and Disease O and N4   (Belgium)

^d Senexis Limited   (United Kingdom)

Author keywords

Alzheimer's disease; APPPS1 21; A toxicity inhibitor; Morris water maze; SEN1500

Indexed keywords

2 FLUORO 5 [5 (3 MORPHOLIN 4 YL PHENOXY)PYRIMIDIN 2 YLAMINO] BENZONITRILE; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; PROTEIN INHIBITOR; SEN 1500; SYNAPTOPHYSIN; UNCLASSIFIED DRUG;

AMNESIA; AMYLOIDOSIS; ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN CELL; BRAIN LEVEL; CEREBRAL AMYLOIDOSIS; COGNITION; CONTROLLED STUDY; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG PENETRATION; DRUG TRANSPORT; ENZYME INHIBITION; LEARNING DISORDER; MALE; MAZE TEST; MOUSE; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PASSIVE AVOIDANCE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PSYCHOLOGIC TEST; RECOGNITION; TASK PERFORMANCE; TASTE AVERSION; TRANSGENIC MOUSE; TREATMENT DURATION; TREATMENT OUTCOME;

ALZHEIMER'S DISEASE; APPPS1-21; AΒ TOXICITY INHIBITOR; MORRIS WATER MAZE; SEN1500;

ADMINISTRATION, ORAL; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; ANILINE COMPOUNDS; ANIMALS; AVOIDANCE LEARNING; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION; HUMANS; LEARNING DISORDERS; MAZE LEARNING; MEMORY DISORDERS; MICE; MICE, TRANSGENIC; MUTATION; NITRILES; PEPTIDE FRAGMENTS; PRESENILIN-1; PYRIMIDINES; SYNAPTOPHYSIN; TASTE;

EID: 84884861186     PISSN: 00283908     EISSN: 18737064     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2013.08.030     Document Type: Article

References (73)

1. P.S. Aisen, S. Gauthier, S.H. Ferris, D. Saumier, D. Haine, D. Garceau, A. Duong, J. Suhy, J. Oh, W.C. Lau, and J. Sampalis Tramiprosate in mild-to-moderate Alzheimer's disease - a randomized, double-blind, placebo-controlled, multi-centre study (the Alphase Study) Arch. Med. Sci. 7 2011 102 111
2. P.S. Aisen, S. Gauthier, B. Vellas, R. Briand, D. Saumier, J. Laurin, and D. Garceau Alzhemed: a potential treatment for Alzheimer's disease Curr. Alzheimer Res. 4 2007 473 478 (Pubitemid 47416642)
3. H. Amijee, and D.I. Scopes The quest for small molecules as amyloid inhibiting therapies for Alzheimer's disease J. Alzheimers Dis. 17 2009 33 47
4. L. Backman The link between knowledge and remembering in Alzheimer's disease Scand. J. Psychol. 39 1998 131 139 (Pubitemid 128471780)
5. C. Bate, M. Tayebi, and A. Williams Ginkgolides protect against amyloid-beta1-42-mediated synapse damage in vitro Mol. Neurodegener. 3 2008 1
6. M. Bentahir, O. Nyabi, J. Verhamme, A. Tolia, K. Horre, J. Wiltfang, H. Esselmann, and B. De Strooper Presenilin clinical mutations can affect gamma-secretase activity by different mechanisms J. Neurochem. 96 2006 732 742
7. P. Bovet, and S. Benhamou Spatial-analysis of animals movements using a correlated random-walk model J. Theor. Biol. 131 1988 419 433
8. H. Braak, and E. Braak Demonstration of amyloid deposits and neurofibrillary changes in whole brain sections Brain Pathol. 1 1991 213 216
9. D.L. Brody, and D.M. Holtzman Morris water maze search strategy analysis in PDAPP mice before and after experimental traumatic brain injury Exp. Neurol. 197 2006 330 340 (Pubitemid 43077140)
10. L.L. Cai, H. Li, J.G. Liu, L.T. Liu, J. Guan, M.F. Liu, J. Hu, and Y. Wei Effects of early intervention with Huannao Yicong formula effective components on behavior and cholinergic system of beta-amyloid precursor protein transgenic mice J. Chin. Integr. Med. 9 2011 292 298
11. Z. Callaerts-Vegh, D. Hoyer, and P.H. Kelly Selective effects of benzodiazepines on the acquisition of conditioned taste aversion compared to attenuation of neophobia in C57BL/6 mice Psychopharmacology (Berl.) 206 2009 389 401
12. M.D. Carter, G.A. Simms, and D.F. Weaver The development of new therapeutics for Alzheimer's disease Clin. Pharmacol. Ther. 88 2010 475 486
13. M.A. Chacon, M.I. Barria, C. Soto, and N.C. Inestrosa Beta-sheet breaker peptide prevents Abeta-induced spatial memory impairments with partial reduction of amyloid deposits Mol. Psychiatry 9 2004 953 961 (Pubitemid 39381959)
14. P.J. Cheng, and M.C. Pai Dissociation between recognition of familiar scenes and of faces in patients with very mild Alzheimer disease: an event-related potential study Clin. Neurophysiol. 121 2010 1519 1525
15. C. Cortes, and V. Vapnik Support-vector networks Machine Learn. 20 1995 273 297
16. S.E. Counts, M. Nadeem, S.P. Lad, J. Wuu, and E.J. Mufson Differential expression of synaptic proteins in the frontal and temporal cortex of elderly subjects with mild cognitive impairment J. Neuropathol. Exp. Neurol. 65 2006 592 601 (Pubitemid 44288943)
17. D.W. Dickson, H.A. Crystal, C. Bevona, W. Honer, I. Vincent, and P. Davies Correlations of synaptic and pathological markers with cognition of the elderly Neurobiol. Aging 16 1995 285 304
18. M. Filali, and R. Lalonde Age-related cognitive decline and nesting behavior in an APPswe/PS1 biogenic model of Alzheimer's disease Brain Res. 1292 2009 93 99
19. J. Foucaud, J.G. Burns, and F. Mery Use of spatial information and search strategies in a water maze analog in Drosophila melanogaster PLoS One 5 2010 e15231
20. M. Gallagher, R. Burwell, and M. Burchinal Severity of spatial learning impairment in aging: development of a learning index for performance in the Morris water maze Behav. Neurosci. 107 1993 618 626 (Pubitemid 23259627)
21. A. Garthe, J. Behr, and G. Kempermann Adult-generated hippocampal neurons allow the flexible use of spatially precise learning strategies PLoS One 4 2009 e5464
22. F. Gervais, J. Paquette, C. Morissette, P. Krzywkowski, M. Yu, M. Azzi, D. Lacombe, X. Kong, A. Aman, J. Laurin, W.A. Szarek, and P. Tremblay Targeting soluble Abeta peptide with tramiprosate for the treatment of brain amyloidosis Neurobiol. Aging 28 2007 537 547 (Pubitemid 46282205)
23. H. Goddyn, S. Leo, T. Meert, and R. D'Hooge Differences in behavioural test battery performance between mice with hippocampal and cerebellar lesions Behav. Brain Res. 173 2006 138 147 (Pubitemid 44604266)
24. J.D. Greene, A.D. Baddeley, and J.R. Hodges Analysis of the episodic memory deficit in early Alzheimer's disease: evidence from the doors and people test Neuropsychologia 34 1996 537 551 (Pubitemid 26154491)
25. H.H. Griffiths, I.J. Morten, and N.M. Hooper Emerging and potential therapies for Alzheimer's disease Expert Opin. Ther. Targets 12 2008 693 704 (Pubitemid 351877298)
26. P. Gronholm-Nyman, J.O. Rinne, and M. Laine Learning and forgetting new names and objects in MCI and AD Neuropsychologia 48 2010 1079 1088
27. J.C. Hailstone, G.R. Ridgway, J.W. Bartlett, J.C. Goll, A.H. Buckley, S.J. Crutch, and J.D. Warren Voice processing in dementia: a neuropsychological and neuroanatomical analysis Brain 134 2011 2535 2547
28. A. Hanna, P. Horne, D. Yager, C. Eckman, E. Eckman, and C. Janus Amyloid beta and impairment in multiple memory systems in older transgenic APP TgCRND8 mice Genes Brain Behav. 8 2009 676 684
29. J. Hardy, and D. Allsop Amyloid deposition as the central event in the aetiology of Alzheimer's disease Trends Pharmacol. Sci. 12 1991 383 388
30. M. Hoefer, S.C. Allison, G.F. Schauer, J.M. Neuhaus, J. Hall, J.N. Dang, M.W. Weiner, B.L. Miller, and H.J. Rosen Fear conditioning in frontotemporal lobar degeneration and Alzheimer's disease Brain 131 2008 1646 1657 (Pubitemid 351806464)
31. C. Janus Search strategies used by APP transgenic mice during navigation in the Morris water maze Learn Mem. 11 2004 337 346 (Pubitemid 38697900)
32. M.E. Larson, and S.E. Lesne Soluble Abeta oligomer production and toxicity J. Neurochem. 120 Suppl. 2012 125 139
33. A.C. Lo, E. Iscru, D. Blum, I. Tesseur, Z. Callaerts-Vegh, L. Buée, B. De Strooper, D. Balschun, and R. D'Hooge Amyloid and tau neuropathology differentially affect prefrontal synaptic plasticity and cognitive performance in mouse models of Alzheimer's disease J. Alzheimers Dis. 37 2013 109 125
34. A.C. Lo, Z. Callaerts-Vegh, A.F. Nunes, C.M. Rodrigues, and R. D'Hooge Tauroursodeoxycholic acid (TUDCA) supplementation prevents cognitive impairment and amyloid deposition in APP/PS1 mice Neurobiol. Dis. 50 2013 21 29
35. A. Lockridge, and L.L. Yuan Spatial learning deficits in mice lacking A-type K(+) channel subunits Hippocampus 21 2011 1152 1156
36. L.F. Lue, Y.M. Kuo, A.E. Roher, L. Brachova, Y. Shen, L. Sue, T. Beach, J.H. Kurth, R.E. Rydel, and J. Rogers Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease Am. J. Pathol. 155 1999 853 862 (Pubitemid 29426831)
37. F. Mangialasche, A. Solomon, B. Winblad, P. Mecocci, and M. Kivipelto Alzheimer's disease: clinical trials and drug development Lancet Neurol. 9 2010 702 716
38. I.C. Martins, I. Kuperstein, H. Wilkinson, E. Maes, M. Vanbrabant, W. Jonckheere, P. Van Gelder, D. Hartmann, R. D'Hooge, B. De Strooper, J. Schymkowitz, and F. Rousseau Lipids revert inert Abeta amyloid fibrils to neurotoxic protofibrils that affect learning in mice EMBO J. 27 2008 224 233
39. C.A. McLean, R.A. Cherny, F.W. Fraser, S.J. Fuller, M.J. Smith, K. Beyreuther, A.I. Bush, and C.L. Masters Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease Ann. Neurol. 46 1999 860 866
40. R. Morris, S. Frey, T. Kasambira, and M. Petrides Ibotenic acid lesions of the basolateral, but not the central, amygdala interfere with conditioned taste aversion: evidence from a combined behavioral and anatomical tract-tracing investigation Behav. Neurosci. 113 1999 291 302 (Pubitemid 29230938)
41. J.J. Nadler, S.S. Moy, G. Dold, D. Trang, N. Simmons, A. Perez, N.B. Young, R.P. Barbaro, J. Piven, T.R. Magnuson, and J.N. Crawley Automated apparatus for quantitation of social approach behaviors in mice Genes Brain Behav. 3 2004 303 314 (Pubitemid 39277417)
42. A. Naert, Z. Callaerts-Vegh, and R. D'Hooge Nocturnal hyperactivity, increased social novelty preference and delayed extinction of fear responses in post-weaning socially isolated mice Brain Res. Bull. 85 2011 354 362
43. Y. Nakagami, S. Nishimura, T. Murasugi, I. Kaneko, M. Meguro, S. Marumoto, H. Kogen, K. Koyama, and T. Oda A novel beta-sheet breaker, RS-0406, reverses amyloid beta-induced cytotoxicity and impairment of long-term potentiation in vitro Br. J. Pharmacol. 137 2002 676 682 (Pubitemid 35333093)
44. E. O'Hare, D.I. Scopes, J.M. Treherne, K. Norwood, D. Spanswick, and E.M. Kim RS-0406 arrests amyloid-beta oligomer-induced behavioural deterioration in vivo Behav. Brain Res. 210 2010 32 37
45. E. O'Hare, D.I.C. Scopes, E.M. Kim, P. Palmer, J. Martyn, A.D. Whyment, D. Spanswick, H. Amijee, E. Nerou, B. McMahon, J.M. Treherne, and R. Jeggo Orally bioavailable small molecule drug protects memory in Alzheimer's disease models Neurobiol. Aging 34 2013 1116 1125
46. K. Ono, and M. Yamada Low-n oligomers as therapeutic targets of Alzheimer's disease J. Neurochem. 117 2011 19 28
47. P.J. Pistell, M. Zhu, and D.K. Ingram Acquisition of conditioned taste aversion is impaired in the amyloid precursor protein/presenilin 1 mouse model of Alzheimer's disease Neuroscience 152 2008 594 600
48. C. Priller, G. Mitteregger, S. Paluch, N. Vassallo, M. Staufenbiel, H.A. Kretzschmar, M. Jucker, and J. Herms Excitatory synaptic transmission is depressed in cultured hippocampal neurons of APP/PS1 mice Neurobiol. Aging 30 2009 1227 1237
49. R. Radde, T. Bolmont, S.A. Kaeser, J. Coomaraswamy, D. Lindau, L. Stoltze, M.E. Calhoun, F. Jaggi, H. Wolburg, S. Gengler, C. Haass, B. Ghetti, C. Czech, C. Holscher, P.M. Mathews, and M. Jucker Abeta42-driven cerebral amyloidosis in transgenic mice reveals early and robust pathology EMBO Rep. 7 2006 940 946 (Pubitemid 44523975)
50. P.H. Reddy, G. Mani, B.S. Park, J. Jacques, G. Murdoch, W. Whetsell Jr., J. Kaye, and M. Manczak Differential loss of synaptic proteins in Alzheimer's disease: implications for synaptic dysfunction J. Alzheimers Dis. 7 2005 103 180
51. S.W. Scheff, S.T. DeKosky, and D.A. Price Quantitative assessment of cortical synaptic density in Alzheimer's disease Neurobiol. Aging 11 1990 29 37 (Pubitemid 20097857)
52. S.W. Scheff, and D.A. Price Alzheimer's disease-related alterations in synaptic density: neocortex and hippocampus J. Alzheimers Dis. 9 2006 101 115 (Pubitemid 44253303)
53. H. Scholtzova, Y.Z. Wadghiri, M. Douadi, E.M. Sigurdsson, Y.S. Li, D. Quartermain, P. Banerjee, and T. Wisniewski Memantine leads to behavioral improvement and amyloid reduction in Alzheimer's-disease-model transgenic mice shown as by micromagnetic resonance imaging J. Neurosci. Res. 86 2008 2784 2791
54. Scopes, D.I., Horwell, D.C., 2011. WO2011144577.
55. D.I. Scopes, E. O'Hare, R. Jeggo, A.D. Whyment, D. Spanswick, E.M. Kim, J. Gannon, H. Amijee, and J.M. Treherne Abeta oligomer toxicity inhibitor protects memory in models of synaptic toxicity Br. J. Pharmacol. 167 2012 383 392
56. D.J. Selkoe Alzheimer's disease is a synaptic failure Science 298 2002 789 791 (Pubitemid 35231524)
57. D.J. Selkoe Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior Behav. Brain Res. 192 2008 106 113
58. D.J. Selkoe, and D. Schenk Alzheimer's disease: molecular understanding predicts amyloid-based therapeutics Annu. Rev. Pharmacol. Toxicol. 43 2003 545 584 (Pubitemid 37372653)
59. C. Soto, E.M. Sigurdsson, L. Morelli, R.A. Kumar, E.M. Castano, and B. Frangione Beta-sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: implications for Alzheimer's therapy Nat. Med. 4 1998 822 826 (Pubitemid 28331024)
60. J. St Andre, and S. Reilly Effects of central and basolateral amygdala lesions on conditioned taste aversion and latent inhibition Behav. Neurosci. 121 2007 90 99 (Pubitemid 46328627)
61. N. Sun, S.A. Funke, and D. Willbold A survey of peptides with effective therapeutic potential in Alzheimer's disease rodent models or in human clinical studies Mini Rev. Med. Chem. 2012
62. C.I. Sze, J.C. Troncoso, C. Kawas, P. Mouton, D.L. Price, and L.J. Martin Loss of the presynaptic vesicle protein synaptophysin in hippocampus correlates with cognitive decline in Alzheimer disease J. Neuropathol. Exp. Neurol. 56 1997 933 944 (Pubitemid 27329114)
63. V. Szegedi, L. Fulop, T. Farkas, E. Rozsa, H. Robotka, Z. Kis, Z. Penke, S. Horvath, Z. Molnar, Z. Datki, K. Soos, J. Toldi, D. Budai, M. Zarandi, and B. Penke Pentapeptides derived from Abeta 1-42 protect neurons from the modulatory effect of Abeta fibrils - an in vitro and in vivo electrophysiological study Neurobiol. Dis. 18 2005 499 508 (Pubitemid 40332709)
64. R.D. Terry, E. Masliah, D.P. Salmon, N. Butters, R. DeTeresa, R. Hill, L.A. Hansen, and R. Katzman Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment Ann. Neurol. 30 1991 572 580
65. D.R. Thal, U. Rub, M. Orantes, and H. Braak Phases of A beta-deposition in the human brain and its relevance for the development of AD Neurology 58 2002 1791 1800 (Pubitemid 34663580)
66. M.H. Viet, S.T. Ngo, N.S. Lam, and M.S. Li Inhibition of aggregation of amyloid peptides by beta-sheet breaker peptides and their binding affinity J. Phys. Chem. B 115 2011 7433 7446
67. D.M. Walsh, I. Klyubin, J.V. Fadeeva, W.K. Cullen, R. Anwyl, M.S. Wolfe, M.J. Rowan, and D.J. Selkoe Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo Nature 416 2002 535 539 (Pubitemid 34288854)
68. D.M. Walsh, and D.J. Selkoe Deciphering the molecular basis of memory failure in Alzheimer's disease Neuron 44 2004 181 193 (Pubitemid 39348839)
69. D.M. Walsh, M. Townsend, M.B. Podlisny, G.M. Shankar, J.V. Fadeeva, O. El Agnaf, D.M. Hartley, and D.J. Selkoe Certain inhibitors of synthetic amyloid beta-peptide (Abeta) fibrillogenesis block oligomerization of natural Abeta and thereby rescue long-term potentiation J. Neurosci. 25 2005 2455 2462 (Pubitemid 40365155)
70. H. Welzl, P. D'Adamo, and H.P. Lipp Conditioned taste aversion as a learning and memory paradigm Behav. Brain Res. 125 2001 205 213 (Pubitemid 33000459)
71. T. Wisniewski, and E.M. Sigurdsson Murine models of Alzheimer's disease and their use in developing immunotherapies Biochim. Biophys. Acta 1802 2010 847 859
72. D.P. Wolfer, R. Madani, P. Valenti, and H.P. Lipp Extended analysis of path data from mutant mice using the public domain software Wintrack Physiol. Behav. 73 2001 745 753 (Pubitemid 32885563)
73. T. Yamamoto Brain regions responsible for the expression of conditioned taste aversion in rats Chem. Senses 32 2007 105 109 (Pubitemid 46017880)